Introducing Cohort 1 of BFI NAMAH at Venture Center, supporting four innovations addressing practical challenges across healthcare. The cohort features solutions for affordable wearable insulin delivery, wound and burn care, non-surgical auditory rehabilitation, and airway monitoring in ICUs. Each innovation takes a focused approach to improving healthcare, making essential technologies more accessible, simplifying treatment, and enabling better monitoring in clinical settings. Through BFI NAMAH, these innovations will receive technical & regulatory support, infrastructure, and mentorship to strengthen their technologies and progress towards adoption.

Introducing Cohort 1 of BFI NAMAH at IKP, bringing together healthcare innovators developing solutions across diagnostics, assistive technologies, digital health, medical devices, and recovery support. From portable point-of-care diagnostics and accessible digital tools to active cooling devices and technology for post-surgical recovery, the cohort reflects the range of challenges that healthcare innovation needs to address. BFI NAMAH at IKP will provide these innovators with access to technical expertise, infrastructure, and mentorship to strengthen their technologies and take the next steps towards clinical use and market adoption. @IKP_SciencePark

Introducing Cohort 1 of BFI NAMAH at IIT Delhi Five innovations, each tackling a different challenge in healthcare, from AI-powered medical imaging and smartphone-based diagnostics to wireless arthroscopy, respiratory monitoring, and simpler, more accessible sample collection. These are innovations being built around real clinical needs: making diagnosis more accessible, bringing advanced capabilities closer to the point of care, and developing tools that can work in the environments where they are needed most. Through the BFI Innovation Full Stack, BFI NAMAH supports innovators across the journey, helping move promising ideas through prototyping, validation, clinical pathways, and towards adoption.

Vaccines provide powerful protection and understanding how that protection lasts can help us protect communities for longer. At CMC Vellore, Dr. Ramya Madhavan and her team, in collaboration with NCBS, are studying immune responses in adults from South India, looking at both antibodies and cellular memory cells to see if protection is holding up years after vaccination. The findings could shape whether India needs booster doses or better surveillance to close the immunity gaps that put communities at risk. Supported by BFI, this research aims to bring India one step closer to lasting protection against these preventable diseases.

“Stronger together” towards zero human deaths from dog-mediated rabies by 2030. Rabies is an infectious zoonotic disease that is 100% fatal once symptoms appear, but also 100% preventable with timely interventions, including post-exposure vaccination. On #WorldRabiesDay, @UNDP_India reaffirms its commitment to support @NCDCMoHFW in efforts to eliminate dog-mediated rabies by 2030. Working with partners including @ADP_health and @BFI_Impact, we strongly advocate for a #OneHealth approach to strengthen the response to zoonotic diseases, including rabies. 🔗Read more about our work: shorturl.at/u0yBE

Corneal blindness is one of the leading causes of preventable blindness in India, yet access to corneal transplantation remains limited by a shortage of donor corneas. Recurrent infections and graft failure can further complicate treatment, creating an urgent need for accessible alternatives. What if a cornea could be 3D-printed? Dr. Vineet Joshi and Dr. Vivek Singh from LV Prasad Eye Institute, together with Prof. Kaushik Chatterjee from IISc Bengaluru, are developing a Digital Light Processing (DLP)-based 3D-bioprinted corneal substitute designed to closely mimic the structure and function of the natural cornea. The project combines three powerful approaches: advanced biomaterials, high-resolution 3D bioprinting and regenerative medicine. The team is developing a transparent, biocompatible and mechanically robust material that can support tissue regeneration and integration. Its drug-eluting capability could also enable localized delivery of therapeutics, potentially helping address infections and reduce disease recurrence. The strength of this collaboration lies in its multidisciplinary expertise. Dr. Vineet Joshi brings clinical and ophthalmic expertise from LV Prasad Eye Institute; Dr. Vivek Singh contributes expertise in ocular regeneration and preclinical animal studies; and Prof. Kaushik Chatterjee brings deep expertise in bioengineering and biomaterials from IISc. Together, they are working to move beyond dependence on donor tissue and develop a scalable alternative for patients affected by severe corneal disease. This research is supported by BFI-BIOME SAMARTH, enabling the team to take the technology from material optimization and fabrication through biological validation and preclinical assessment.

Honoured to meet Shri Nara Lokesh, Minister for IT, Electronics & Communication, Human Resources Development, and RTG, Government of Andhra Pradesh. The Minister's vision for Andhra Pradesh brings healthcare, science, and technology into one ecosystem, from a world-class hospital and research hub in Visakhapatnam to a planned biotechnology park and Amaravati Quantum Valley. It is a rare and ambitious approach, one that gives science and its innovators room to scale. At BFI, we support the researchers, clinicians, and founders who are the backbone of such an ecosystem. We shared how our philanthropic support is helping strengthen the biomedical pipeline at every stage, from early-stage research to healthcare innovation to startups taking their first steps. We believe that when public vision meets catalytic philanthropy, the system moves faster and the impact reaches further. Grateful for the Minister's time and for a thoughtful conversation on the future of India's biomedical sector.

The Interconnect Innovation Catalyst Program | Cohort 2 is now open for applications. Calling all innovators turning research into prototypes, prototypes into products, and ideas into solutions that can make a difference in healthcare. Built for biomedical innovators at TRL 4+, the program will select up to 50 fellows for Cohort 2, providing up to ₹30 lakh over 12 months through milestone-based quarterly funding, along with mentorship, strategic guidance, clinical and industry connections, and access to a national network of innovators and ecosystem partners. No equity. No IP claims. If you’re building a solution with the potential to shape the future of healthcare, this is your opportunity to take it further. Deadline: 9 November 2026 To Apply download the Interconnect App: Google Play Store: play.google.com/store/apps/d… Apple App Store: apps.apple.com/in/app/interc… Learn more: blockchainforimpact.in/open-…

Doctors will be replaced by AI. Doctors who use AI will replace those who don’t. AI will always remain an assistant to doctors. What are your thoughts? Watch the full podcast here: youtube.com/watch?v=iySSZf28…

Building a growing network of medical institutions across India Through the BFI-BIOME Medical INI Program, BFI-BIOME SAMARTH Program, and Medical College Incubation Centers, we are building a growing network of leading medical institutions across India. These partnerships support translational research and clinical innovation addressing critical healthcare challenges across infectious diseases, non-communicable diseases, cancer, rare diseases, antimicrobial resistance, genomics and proteomics, diagnostics, and novel medical technologies. BFI is creating pathways for promising research and clinical insights to move towards practical healthcare solutions and patient impact.

Announcing Cohort 1 under the Medical College Incubation Centers Program The innovators will work inside a hospital-embedded ecosystem, with direct access to clinicians, hospital infrastructure, and structured pathways for ethics approval and clinical validation. From prototype to clinical adoption, this is where healthcare innovation gets tested in the real world. The Cohort: •⁠ ⁠Dr. Garima S Jain - MIRNOW LLP: Minimally invasive blood test for prostate cancer risk assessment •⁠ ⁠Sidesh Kumar - Lenek Technologies: AI-assisted digital X-ray for TB & lung disease detection •⁠ ⁠Hariharan Ramanathan - SHA (Med) Compliance and Services: Hospital compliance, regulatory readiness, & accreditation platform •⁠ ⁠Naveen Soni - 2HEART: Vascular health monitoring smart device •⁠ ⁠Anamika Mishra Pandey - TanPrish Dynamics: ColpAI, AI-based cervical cancer screening •⁠ ⁠Dr. Swarnim - KidneyCareAI: AI-powered kidney health monitoring •⁠ ⁠Pranay Agarwal - Diagno+: AI multi-cancer diagnosis platform @NimsUniversity

As we age, maintaining muscle becomes increasingly difficult. Muscle loss can also occur with chronic diseases, prolonged bed rest, cancer, diabetes and certain medications. And while exercise and nutrition remain important, what happens when someone needs to preserve their muscle but is physically unable to exercise? This is a growing challenge. India already has more than 156 million people aged 60 and above, representing 11% of the population, and this is projected to rise to 21% by 2050. Studies suggest that sarcopenia, the progressive loss of muscle mass and strength, affects around 35% of people studied in India, although estimates vary depending on how it is diagnosed. Source: ijmr.org.in/prevalence-and-d… There is currently no approved drug specifically for sarcopenia, leaving a significant unmet need for patients who cannot rely on exercise alone. Source: pubmed.ncbi.nlm.nih.gov/4216… At CSIR-CDRI, Dr. Sabyasachi Sanyal, Dr. Atul Goel, Dr. Jiaur Rahaman Gayen, Dr. Rajdeep Guha, and Dr. Virendra Prajapati are working to change this. Supported by BFI-BIOME, the team is developing small-molecule adiponectin receptor agonists designed to activate pathways involved in muscle metabolism and regeneration. Their hit molecules, Medicarpin and CDRI-1709S, have shown promising results in cell and animal models, including protection against muscle atrophy and improvements in muscle function after oral administration. pubmed.ncbi.nlm.nih.gov/4263… pubmed.ncbi.nlm.nih.gov/4248… Several lead molecules derived from these hits are currently being evaluated at the preclinical stage, with the researchers working toward establishing a candidate that could eventually progress through further development and, if successful, clinical trials. The potential outcome? An oral therapy that could help preserve muscle mass and strength when exercise is not an option, offering a new therapeutic approach to muscle wasting.

1.5 crore+ Indians with diabetes suffer from ulcers, and for many, these wounds lead to amputation. One of the biggest factors? Chronic wounds can get stuck in the inflammatory stage of healing, preventing new tissue from forming. Serigen’s silk protein based products are designed to reduce inflammation and support the wound’s transition toward tissue formation. Know someone dealing with a chronic wound? Share this with them. It could help them discover a better approach to wound healing.

One of the most important factors that saved countless lives during the pandemic was all the institutions coming together to address the problem. But has it left us better prepared for Disease X? Watch the full podcast here: youtube.com/watch?v=iySSZf28…

We're hiring a Graphic Designer. Help us turn complex ideas into clear and compelling visuals campaigns, infographics, and more. 3+ years in B2B design, fluency in Adobe Creative Suite, Figma, and PowerPoint required. Apply via: blockchainforimpact.in/caree…

India had an estimated 115.1 million people living with chronic kidney disease in 2017, highlighting the urgent need for accessible and timely kidney function testing. Source: Global Burden of Disease Study, published in PubMed Central pmc.ncbi.nlm.nih.gov/article… Early detection can help prevent or slow further kidney damage, yet conventional creatinine testing depends on pathology labs, creating delays and limiting screening, especially in underserved areas. Supported by BFI-BIOME, Utopic Tech is changing that with Creasens, a portable point-of-care device designed to bring kidney-function assessment closer to the patient. Creasens need just 10 µL of blood from a finger prick to measure creatinine, a key marker used to assess kidney function. The device then uses the creatinine result, along with age and gender, to calculate eGFR (estimated glomerular filtration rate), a measure of how effectively the kidneys are filtering waste from the blood. Results are generated in just 3 minutes. At its core, Creasens uses a biosensing-based measurement system to detect creatinine in the blood and convert that biological signal into a quantitative result. Its compact, portable design means testing can move beyond centralized laboratories to clinics, hospitals, screening camps and rural healthcare settings. Utopic Tech’s validation study reports 97% overall diagnostic accuracy compared with a central laboratory reference method. The potential impact is significant: less waiting, fewer barriers to testing and more opportunities to identify kidney problems earlier, particularly in communities where access to laboratory diagnostics is limited.

Introducing the First Cohort under the Product Promotion Program - BFI Innovation Full Stack 8 startups. 8 healthcare innovations. One shared mission: market adoption. These ventures have moved beyond validation and into the Product Promotion Program, where a dedicated team of market experts, working across major cities nationwide, will help take proven healthcare innovations to doctors, hospitals, distributors, and government procurement channels. Meet the cohort: •⁠ Cre-AID Labs: MITHRIL Splints®️, custom orthopaedic splints & orthoses •⁠ MedevPlus: IXanner®️ 7VN, the world's first portable handheld OCT •⁠ Inochi Care: InoHeal™️ Pro, multi-therapeutic wound healing device •⁠ CareMother by Doto Health: Maternal & fetal monitoring solutions •⁠ SmartQR Technologies: AI-enabled Mini DNA Lab •⁠ Serigen Mediproducts (Official account): Seriderm, silk-protein wound dressing •⁠ ⁠SparshMind Innovations Pvt. Ltd.: VR-based neuro rehabilitation solution •⁠ Cureous Labs: Eturnal Series, India's first intelligent automatic patient repositioning solution Learn more: bmascent.com/medtec-solution…

GLP-1-like drugs have become one of the biggest stories in modern medicine, especially for treating obesity and other metabolic diseases. At the same time, there is an ongoing debate around their affordability, accessibility, long-term use, and whether these treatments can become sustainable solutions for everyone. One thing is clear: countries like India urgently need innovative and scalable approaches to tackle lifestyle-associated diseases such as obesity, diabetes and metabolic dysfunction, which are affecting an increasingly large population. Supported by BFI-BIOME, Dr. Bhabatosh Das and Dr. Dinesh Mahajan at THSTI are engineering a beneficial gut bacterium, E. coli Nissle 1917, to produce and release GLP-1-like peptides directly inside the gut. Think of it as turning bacteria into living drug factories. Instead of repeatedly delivering drugs from outside the body, these engineered bacteria could potentially produce therapeutic molecules where they are needed, helping regulate appetite, improve metabolism and address obesity and fatty liver disease. The team is now testing their safety, stability and effectiveness in animal models. @THSTIFaridabad

India is home to millions of people living with diabetes, yet advanced insulin-delivery technologies remain out of reach for many. Insulin pumps can cost up to ₹6 lakh, with recurring expenses adding to the burden, making affordability a major barrier to adoption. This is the problem Open MedLabs is working to address. The company is developing Insuflo, an affordable insulin pump designed for the Indian healthcare landscape. Ideated at the Utsaah Laboratory at IISc Bengaluru, Insuflo aims to make advanced insulin-delivery technology more accessible. So, how does it work? Insuflo uses a patented mechanism designed to provide precise dosing and detect blockages in delivery very quickly. It can also adapt insulin delivery to an individual’s needs and lifestyle patterns, helping make diabetes management more responsive and personalised. Supported by Blockchain for Impact (BFI), Open MedLabs is working to bring this innovation closer to the people who need it most. Led by Deval Karia, Founder & CEO, and Prof. Manish Arora, the company is rethinking how medical devices can be designed for resource-constrained settings. From expensive technology accessible to few, to an affordable solution designed for India.